Some muscles are resistant to the loss of motor neurons seen in patients with spinal muscular atrophy, and new research has ...

DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II ...

Jeffrey Jenkins, a 38-year-old aspiring surgeon, dedicated his life to medicine - but his world came crashing down with a ...

In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...

Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not ...

On 30 December 2024, Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached ...

Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully ...

QRL-101 is under clinical development by QurAlis and currently in Phase I for Epilepsy. According to GlobalData, Phase I drugs for Epilepsy have an 84% phase transition success rate (PTSR) indication ...

This confirmation follows the Company's successful efforts to improve its balance sheet by raising new equity and reducing outstanding liabilities. As a result, NeuroSense shareholders' equity now ...

Magnesium threonate has been shown in some animal studies to enhance cognitive function by raising magnesium ions in the ...

Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully achieved the primary endpoint in a Phase III STEER study (NCT05089656) ...